Vaccinia DynPort Vaccine Company LLC - Treatment for Complications of Smallpox Vaccination
Vaccinia Immune Globulin Intravenous (VIGIV) is the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination.Posted: February 2005
Related articles
Vaccinia (vaccinia immune globulin intravenous (human)) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
